Recently, Baiyunshan and Meishi Medical Holdings Co., Ltd. formally signed a letter of intent for cooperation in the Guangzhou Municipal Government. The two parties intend to establish a joint venture company and invest about 300 million yuan to jointly build a high-end medical device R&D and production base with independent intellectual property rights in the Guangzhou Development Zone. Not long ago, Kangzhi Pharmaceutical and Beijing Hengzhuo Technology Holdings Co., Ltd. also held a signing ceremony in Guangzhou to jointly promote the development of cochlear implant technology in the domestic market. "The pharmaceutical and medical device industries are very different and can be said to be completely different." Tao Yuchun, a senior expert in the medical device industry , said in an interview with this reporter. In his view, some pharmaceutical companies are currently interested in investing in medical equipment. On the one hand, pharmaceutical companies are not bad money and have a willingness to invest. On the other hand, medicines and medical equipment have the same customer and hospital channels, and pharmaceutical companies can borrow them. The original drug marketing channel leveraged its own resources and traditional channel advantages. Under the background of the overall slowdown in the pharmaceutical manufacturing industry, medical devices have become a new profitable “straw†in the process of enterprise transformation and upgrading. Since last year, the social capital business has obviously accelerated, and pharmaceutical companies that are not bad money have invested in or purchased hospitals frequently. After the pharmaceutical company from the medical tide, in 2016, will the pharmaceutical companies come from the equipment tide? Transformation is as difficult as re-starting The market prospects for medical devices and diagnostic reagents are promising. The average annual growth rate in China is over 25%, which is higher than the growth rate of the pharmaceutical industry. However, China's medical equipment only accounts for about 13% of the total sales revenue of the pharmaceutical industry, far below the overall level of 50% in Europe and the United States, and has huge market potential. According to the data of China Chamber of Commerce for Import and Export of Medicines and Health Products, from January to November 2015, the import and export volume of medical equipment in China was 34.589 billion US dollars, up 7.73% year-on-year, and the growth rate was 3.46 percentage points higher than the same period of the previous year. Bio Valley predicts that financing in 2016 will be an important theme for the medical device industry. As the merger progresses, the number of acquirers in the market will further decrease, and many companies will face difficulties in financing difficulties in the coming year. However, the implementation of the IPO registration system will solve this problem to some extent. In addition, many competitors from the pharmaceutical industry will also promote the rapid development of this industry, and many large pharmaceutical companies regard the medical device field as the next growth point of the pharmaceutical industry. However, from the practical level of operation, pharmaceutical companies will face many difficulties in moving to medical equipment. Shi Lichen, founder of Beijing Dingchen Medical Management Consulting Center, told reporters that although the drug and medical equipment are facing the same market, it is expected that there will not be too many pharmaceutical companies to take care of this year, because the difficulty in transforming from pharmaceutical to medical equipment can be repeated. Start a business. "The medical barriers are high, and the technical bottlenecks must be broken. The pharmaceutical companies do not have the technology and production equipment. In addition, the operating system must be re-introduced, and it needs to be properly applied after a period of time. In the later period, there are problems in service matching. Need to follow up comprehensively." The aforementioned experts pointed out that the net profit of different medical equipment products is very different. On the whole, the profit of medical equipment is higher than that of medicines. Pharmaceutical companies have tested the resource integration capabilities of pharmaceutical companies, such as seeking good partners or acquiring a highly skilled medical machinery company. The reporter noted that according to the "Cooperation Letter of Intent", Guangyao Baiyunshan and Meishi Medical will complement each other's resources in terms of capital, product technology and market, including the advantages of Guangyao Baiyunshan in terms of capital and sales network; The advantages of medical treatment in new technologies and new products will jointly expand the medical equipment business. Guangyao Baiyun Mountain is funded by cash, accounting for 60% of the shares; Meishi Medical is funded by “cash + technologyâ€, accounting for 40% of the shares. The two parties plan to jointly build a high-end nuclear magnetic resonance production base. The first phase is to produce pediatric and orthopedic professional MR machines. Meishi Medical Co., Ltd. promises to transfer the above-mentioned equipment related to product registration, technology and patents to the joint venture company in an appropriate manner. Handheld Ultrasound Scanner,Handheld Ultrasound Machine,Medical Ultrasound Instruments,Animals Veterinary Ultrasound Scanner Mianyang United Ultrasound Electronics Co., Ltd , https://www.uniultrasonic.com